Graphite Bio Completes Merger with LENZ Therapeutics; Combined Company to Trade as LENZ

Werewolf Therapeutics and Ambros Therapeutics Merge in $150M PIPE to Advance Neridronate Phase 3

August 23, 2026

Pharmaceuticals

Werewolf Therapeutics and Ambros Therapeutics entered into a definitive all-stock merger agreement, with a concurrently announced, oversubscribed $150 million private placement expected to fund development of neridronate through pivotal Phase III results and a planned FDA submission. The combined company will operate as Ambros Therapeutics, be headquartered in San Diego, and is expected to trade on Nasdaq as AMBX.

Fulcrum Therapeutics and Slate Medicines Announce Definitive All-Stock Merger With $245M Private Placement

August 21, 2026

Biotechnology

Fulcrum Therapeutics and Slate Medicines entered into a definitive all-stock merger agreement to combine into a Nasdaq-listed biotechnology company operating as Slate Medicines under ticker SLTE. The transaction is supported by an oversubscribed concurrent $245 million private placement led by Frazier Life Sciences, with committed participation from multiple healthcare investors and expected to fund operations into 2029.

LianMedical Completes Merger Between LianBio and LianMedical

July 17, 2026

Medical Devices

LianMedical (formerly LianBio) announced the completion of its previously announced merger between LianBio and LianMedical. Under the approved plan of merger, LianMedical merged with and into LianBio, and LianBio continued as the surviving company, with the company changing its name to LianMedical effective upon completion.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

Graf Acquisition Corp. IV Completes Business Combination with NKGen Biotech

October 2, 2023

Biotechnology

Graf Acquisition Corp. IV completed its previously announced business combination with NKGen Biotech, Inc., resulting in NKGen becoming a wholly‑owned subsidiary and the combined company listing on Nasdaq under the ticker NKGN. The transaction provides NKGen with access to public markets and capital to accelerate development and commercialization of its autologous, allogeneic and CAR‑NK cell therapy programs.

Blueprint Medicines Acquires Lengo Therapeutics

November 29, 2021

Biotechnology

Blueprint Medicines has entered a definitive agreement to acquire privately held precision oncology company Lengo Therapeutics for $250 million in cash plus up to $215 million in regulatory- and sales-based milestones. The deal adds Lengo’s lead oral EGFR exon 20 insertion candidate LNG-451 and other preclinical precision oncology programs to Blueprint’s lung cancer portfolio, expanding its capability in brain-penetrant EGFR inhibitors.